Moody’s downgrades Senegal to Caa1 amid rising debt concerns
Oric Pharmaceuticals (NASDAQ:ORIC) CEO Jacob Chacko sold 37,461 shares of company stock on October 6, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $12.32, fetching a total of $461,519. The sale comes as ORIC trades near its 52-week high of $14.93, with the stock showing remarkable momentum, gaining over 230% in the past six months. According to InvestingPro analysis, technical indicators suggest the stock is currently in overbought territory.
The transactions occurred within a price range of $12.07 to $12.59. This sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted by Chacko on June 21, 2025. Following the sale, Chacko directly owns 531,419 shares of Oric Pharmaceuticals.
In addition to the directly held shares, Chacko also holds rights to receive 178,667 shares of Oric Pharmaceuticals as restricted stock units and stock options to purchase 3,378,000 shares.
In other recent news, ORIC Pharmaceuticals has been the focus of several analyst firms and company developments. Jefferies raised its price target for ORIC Pharmaceuticals to $23, maintaining a Buy rating, following the company’s strategic focus on its ’944 mCRPC and ’114 NSCLC programs. Guggenheim initiated coverage with a Buy rating and set a price target of $18, highlighting the potential of ORIC’s lead drug, ORIC-944. Ladenburg Thalmann also initiated coverage with a Buy rating and a $15 price target, emphasizing the promising profile of ORIC-944.
Cantor Fitzgerald reiterated an Overweight rating on ORIC Pharmaceuticals, noting the stock’s undervaluation and the potential of its oral PRC2 inhibitor, ORIC-944. Additionally, ORIC Pharmaceuticals announced the appointment of Kevin Brodbeck as Chief Technical Officer, a new role created as the company prepares for potential Phase 3 trials in 2026. These developments signal a period of strategic growth and focus on advancing ORIC’s cancer treatment candidates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.